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i
Summary: A radioassay for the measurement of cortisol binding capacity in human serum was developed
and the results validated by radioimmuiioassay of serum corticosteroid binding globulin. The mini-scale
method is simple, reliable and rapid, and avoids Separation of partitioned phases. The linear correlation
between the free cortisol index and free cortisol concentration äs calculated by the two methods utilizing
serum samples with normal and abnormal protein concentrations was r = 0.962 (n = 114, p < 0.001) and
the regression equation was y = 3.51 6 — 2.632. The teehnique requires no preparation of reagents, and
the assay can be performed in 45 minutes using 0.05 ml of serum or plasma.
_ In recent years, assays of salivary cortisol have beenintroduction , . * v . t 1<t x A ~advocated äs a reliable alternative test for assessing
Corticosteroid binding globulin (CBG; synonym adrenal Status, since direct techniques for the mea-
transcortin) binds Cortisol, and to a lesser extent some surement of unbound "free" cortisol in plasma are
other sterpids, with relatively high affinity and low not available (3). For serum samples, the most com-
capacity. The physicochemical characteristics and mon methods so far described involve the combined
clinical relevence of this protein have been compre- estimation of total plasma cortisol and its free frac-
hensively reviewed elsewhere (l, 2). Cortisol circulates tion estimated by one of the following techniques:
in the human blood stream in bound (about 75% of binding eapacity by equilibrium dialysis (4), ultrafil-
total cortisol tightly to corticosteroid binding globu- tration (5), steady state gel filtration (6) or dextran
lin and 10% loosely to albumin) and unbound frac- coated charcoal (7); other methods rely on the mea-
tions. Measurement of the latter in plasma is consid- surement of total cortisol and direct estimation of
ered to be clinically more appropriate, since it reflects corticosteroid binding globulin by immunochemical
the physiologically active form of the circulating cor- or radioimmunoassay (RIA) techniques (8, 9). The
tisol, and provides reliable Information, especially in major disadvantages of these methods include cum-
cases of altered corticosteroid binding globulin levels. bersome procedures, preparation of special reagents,
Measurement of the unbound fraction is therefore unsuitability for automation, relatively large sample
expected to become a frequently ordered test. volumes or high cost.
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We describe the development of a reliable, inexpen-
sive and basically versatile technique for the measure-
ment of patient plasma/serum binding eapacity for
cortisol, which can be used in conjunction with the
total cortisol level to estimate the free cortisol.
Subjects, Materials and Equipment
Subjects
Morning blood samples (10 ml) were obtained during fasting
from 13 male and 18 female volunteers (not using oral contra-
ceptives), 22 samples from 11 patients before and 12 hours
after a single oral dose (1.0 mg) of dexamethasone (Roussel
Lab. Ltd., London, U. K.), 15 samples from 5 patients subjected
to a short synacthen test (i. v. injection of 0.25 mg tetracosac-
tide: cortrosyn®; Organon, Oss, Holland), 24 morning and
evening samples from 12 patients, and 22 samples from preg-
nant women at various stages of gestation (15—40 weeks). The
serum samples were stored at —20 °C until assayed.
Materials
All %4Analar" grade chemicals and solvents were obtained from
BDH chemicäifc (Poole, U.K.). [l,2,6,7-3H]cortisol, 3145 GBq/
mmol in (9:1) toluene: ethanol (cat. no. 407) was obtained
from Amersham International (Bucks, U.K.), and unlabelled
cortisol was from Steraloids Ltd. (Croyden, U. K.). Total corti-
sol RIA kits were obtained from Corning Medical and Scientific
(Medfield, Massachusettes 02052, USA) and CBG RIA kits
from Institute National Des Radioelements (Fleurus, Belgium).
Phosphate buffer, 0.1 mol/I pH 8.0, was used throughout unless
otherwise stated. Toluene containing 4 g/l 2,5-diphenyloxazole
(PPO) and 0.04 g/l l,4-bis2-(4-methyl-5-phenyloxazole) benzene
(DM-POPOP) was used äs a scintillant.
Equipment
Beta counting was performed with an LKB Rack Beta liquid
scintillation counter model 1217 (Bromma, Sweden).
Quench was determined by the channels ratio rnethod, using
an external set of quenched Standards consisting of 7 ampoules
containing different quantities of quenching agent (carbon te-
trachloride) and identical amounts of radioactivity (cat. no.
QCR 50, Amersham International). Using the quench correc-
tion, counts were converted to disintegrations per minute.
Assays were carried out in 15 55 mm disposable plastic
scintillation mini vials obtained from Wheaton Scientific, N.J.
08332, USA.
Methods and Results
Preparation of corticosteroid binding
bulin Standards
lo-
A pool of late pregnancy serum was obtained from women at
over 28 weeks of gestation. Six dilutions were prepared in a
pool of male serum which had been preheated at 60 °C for 2
hours. The corticosteroid binding globulin concentrations of
these Standards were estimated by a modification of the Rosner
method (10) where the binding protein is saturated with tritiated
cortisol then precipitated with ammonium sulphate, and the
mass of bound cortisol is detennined from the known speciflc
activity of the added steroid. The Standards (with an assigned
value of 35, 70, 150, 300, 700, and 1500 nmol/1) were aliquoted,
and stored at —20 °C until used.
Principle of the method
A fixed quantity of buffered 3H-labelled cortisol is
added to all samples and Standards. After equilibrium
is attained, a fixed volume of toluene^based scintilla-
tion liquid is added, foliowed by short vortex mixing
and the radioactivity estirnated JIJL a liquid scintillation
counter at 4 °C.
The unbound cortisol immediately becomes parti-
tioned into the organic solvent while protein-bound
cortisol remains within the aqueous phase. The
aqueous fraction makes no contribution to the
photon yield of the scintillation System. Hencej a
direct relationship exists between the amöunt of 3HU
labelled cortisol bound to plasma proteins (mairily
corticosteroid binding globulin) and the decrease of
total radioactivity.
This priiiciple is supported by the following facts:
1. The observed quenching process is not asspciated
with a concomitant shift in the 3H energy spectrum
(fig. 1); and
2. A linear Scatchard plot is obtained wheri dialysed
serum pools are incubated with varying quantities of
3H-labelled cortisol (fig. 2).
Optimization of assay conditions
Scintillant volume
Three concentrations of 3H-labelled cortisol with var-
ious scintillant volumes ranging ffom 0.5 to 3.5 rnl
were counted. A plateau was reached at aboüt 2.5 inl
of scintillant (fig. 3), indicäting no significant gains
in counting efficiency if the volume of the scintillant
was further increased. This volume was therefore
used in all subsequent studies.
Effect of pH and incubation time
Using pregnancy or normal serum pools, 0.2 ml pf
buffered 3H-labeled cortisol (660 Bq) was ineubated
at 37 °C with 0.05 ml of serum, foliowed by additiön
of 2.5 ml of scintillant in one set, buffers of various
pH ranging from 4 to 10 were used, while in the
second set, assay tubes were incubated for various
periods of time ranging from 0 to 120 min. A pH of
8.0 and an incubation time of 30 minutes were found
to be optimal äs shown in figures 4 and 5 respectively.
Dissociation rate of binding'prptein-cörti-
sol complex
Using the optimized conditions described above, a
Standard curve was constructed, aiid serial counting
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Fig. 2. Binding of pH]cortisol to a pool of normal serum either
alone (o) or in the presence of 100-fold molar excess of
unlabelled Cortisol (o). Saturable binding, calculated äs
the difference between the results in the presence and
absence of excess unlabelled cortisol, is represented by
the method of Seatchard in the inset. Equilibrium con-
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Fig. 3- The effect of increasing scintillant volume on the total
counts of a fixed quantity of pH]cortisol containing 330
(a), 660 (o), and 1320 (A) Bq.
of radiöactivity was perfonned immediately and after
100 minute intervals. The fraction of decrease in
quenching was found to be 0.045 per hour at the
lowest end and 0.072 per hour at the highest end
of the Standard curve. However, these rates were
gradually reduced to less than 0.01 per hour after the
first five hours. Thus, the effect öf such dissociation
was deemed relevant only for large routine assays,
where under these circumstances either the Standard
curve is counted repeatedly after every 30 samples or
counting of the whole assay is delayed for 3 hours
after toluene additiön.
Haemolysis
Heparinized erythrocytes were washed with saline
and sübjected to 3 cycles of freezing and thawing.
The haemoglobin epntent of the haemolysate was
determined and incremental amounts of it were added
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Fig. 4. The effect of pH on the binding (expressed s fraction
of quenching) of [3H]cortisol to pools of normal (o)













Fig. 5. The effect of increasing incubation time on the binding
(expressed s fraction of quenching) of pHJcortisol to
pools of normal (o) and pregnancy (o) sera.
to 3 serum samples which were assayed by the present
method. Haemoglobin up to 6.5 g/l did not appear
to interfere with the assay.
Precision
The within-batch coefficient of Variation, assessed by
10 simultaneous analyses of samples with low, normal
and high concentration of corticosteroid binding glo-
bulin were 8.9, 5.2, and 6.8% respectively. The
between-batch coefficient of Variation, assessed by
analysis of a normal sample in 5 consecutive assays,
was 8.2%.
Final assay protocol
The assay is carried out in mini vials. Reagents are
added in duplicate s follows:
0.05 ml of Standard or patient serum; 0.2 ml of 3H-
labeled cortisol (660 Bq) in phosphate buffer; incuba-
tion at 37 °C for 30 min; addition of 2.5 ml of scintil-
lation liquid. Radioactivity was measured in a liquid
scintillation counter. A typical Standard curve is
shown in figure 6.
Calculation of Free Cortisol Index: The following
equation was utilized for estimating the Free Cortisol
Index:
FCI = Serum Total Cortisol (nmol/1)
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Fig. 6. A typical Standard curve for the radioassay of human
serum binding capaeity for cortisol. Bach point repre-
sents the mean of triplicate determinations ± l SD.
Corticosteroid binding globulin by radioim-
inunoassay
Serum concentrations of corticosteroid binding glo-
bulin were measured by a commercial radioimmuno-
assay kit and the free cortisol concentrations were
estimated according to the man facturer's instruc-
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tions. According to the marmfacturer, the validity of
such estimations has been proved by comparison
with free cortisol levels determined by Ultrafiltration
(n = 60, r = 0.9444, y = 0.892 χ + 1.38 nmol/1).
Clinical observations in normal and patient
samples
As expected, no statistically significant differences
were detected in the values for binding capacity or
actual corticosteroid binding globulin levels between
apparently normal males and females. Furthermore,
pregnancy samples exhibited higher levels for both
Parameters s shown in table l.
The serum binding capacity was inversely related to
changes in cortisol concentrations, e. g. the decrease
of cortisol in the dexamethazone suppression test, the
rise during the short synacthen test, and the decline
in midnight levels (fig. 7).
The relationship between the estimates of free cortisol
concentration (obtained from total cortisol and corti-
costeroid binding globulin concentration) and free
cortisol index (obtained from total cortisol and values
of binding capacity), shown in figure 8, gave a corre-
lation coefficient of r = 0.962 and a linear regression
equation y = 3.516 χ — 2.632.
These results indicate that the method we have devel-
oped has quite acceptable limits of specificity and
sensitivity for clinical application.
Discussion
It is well established that serum cortisol is in a state of
dynamic equilibrium with both corticosteroid binding
globulin and albumin, and that these two proteins
form quantitatively significant dissociable complexes
with some other steroid hormones (e. g., progesterone
Tab. l. Estimated values (mean ± l SD) for total cortisol, cortisol binding capacity,. corticosteroid binding protein by RIA, free
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Fig. 7. Comparison of values for cortisol binding capacity in
patient's matched samples during the dexamethasone
suppression test, the short synacthen test, and circadian
rhythm.
Fig. 8. A scatter plot showing the correlation between the free
cortisol concentrations and indices, together with the
linear regression.
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(11)). Furthermore, there are many clinical situations
(including for example pregnancy, nephrotic syn-
drome, hepatic diseases (12, 13)) in which, because
of altered serum protein binding capacity for cortisol,
commonly performed assays of serum total cortisol
may provide a poor index of adrenocortico-metabolic
Status. Direct techniques for the measurement of the
biologically active free cortisol are äs yet unavailable.
An alternative approach to the estimation of this free
fraction is based on the law of mass action, and it
can be calculated if the concentrations of both serum
total cortisol and either corticosteroid binding glöbu-
lin or measure of the protein binding capacity for
cortisol are known.
However, in contradistinction to corticosteroid bind-
ing globulin measurement by radioimmunoassay,
which admittedly offers better technical levels of sen-
sitivity and specificity, the serum binding capacity
technique should provide, on theoretical grounds at
least, clinically more relevant estimates of the free
cortisol fraötions in patient sera, since it takes into
account the following:
1. variable serum albumin binding capacity;
2. the presence of other competing biological and/or
synthetic steroids;
3. aggregated/non binding molecular forms of corti-
costeroid binding globulin;
4. immunologically distinct but active genetic vari-
ants of corticosteroid binding globulin if present.
Thus, the method we have developed measures serum
binding capacity for cortisol, and is based on the
principle of competitive binding of tritiated cortisol,
under non-saturating conditions, to corticosteroid
binding globulin and albumin. It relies on a phase
partition technique to separate bound from free corti-
sol fractioris.
The principai advantages of the present method are:
convenience, low cost, long shelf life of reagents, and
adeqüate specificity and accuracy for routine clinical
use. The assay requires no conyeiitional Separation
Step. Automation or predilution of samples are there^
fore possible, and the assäy can be performed in a
relatively short time. Furthermore, the total analyti*·
cal procedure, from mixiiig the reactants to the actual
counting, is performed in one mini vial, with a conse-
quent reduction in cost.
In comparison with other methods, our protocol de-
scribed here yields values for serum binding capacity
for cortisol (230 mmol/1) which are similar to those
reported by öthers (1). In addition, an estimate of
the equilibrium constant of cortisol with its binding
proteins (5.48 nmol/1), äs obtained by Scatchard
analysis of Saturation plots, is similar in magnitude
to those quoted in the literature (l, 14). Furthermore,
results of binding capacity obtained by this technique
have a highly significant correlation with their corre^
sponding corticosteroid binding globulin estimates by
radioimmunoassay.
In conclusion, we have presented a routine laboratory
method for measuring serum protein binding for cor-
tisol that can be applied, in conjunction with the
concentration of serum total cortisol, to provide valu-
able Information relevant to the diagnosis and/or
therapeutic choices in relation to adrenocortical func-
tion.
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